Belantamab mafodotin induced deep and durable responses in relapsed refractory myeloma patients

What is the DREAMM-5 platform trial?
The DREAMM-5 platform trials studies the single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugates.

In this video:
Dr. Paul G. Richardson (Dana Farber Cancer Institute — Boston) explains that belantamab mafodotin induced deep and durable responses in patients with relapsed refractory multiple myeloma with a manageable safety profile. He describes how this platform trial design allowed for efficient evaluation of belantamab mafodotin in combination with other anti-myeloma agents, such as a humanized wild-type IgG1 anti-OX40 agonist, an IgG4 inducible T-cell costimulatory (ICOS) agonist, and a gamma-secretase inhibitor.

Conclusion:
The unique, multimodal mechanisms of action (MoAs) of belantamab mafodotin, in combination with MoAs of these agents, has the potential to achieve synergistic effects in MM, to further enhance anti-myeloma activity without compromising safety.

Clinical trial information: NCT04162210

PAUL G. RICHARDSON, MD

Paul G. Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. He is also an Institute Physician and a RJ Corman Professor of Medicine, at Harvard Medical School in Cambridge, MA. In addition to multiple myeloma, his key clinical interests are regimen-related toxicity, stem cell transplantation, experimental therapies and cancer pharmacology, and more. Visit Dr. Paul Richardson’s full biography.